Status:
COMPLETED
Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35-80 years
Phase:
PHASE3
Brief Summary
To determine, in subjects with Type 2 Diabetes Mellitus: 1. Whether glycemic control can be achieved at least as effectively with an insulin regimen involving pre-meal EXUBERA™ (inhaled insulin) plus...
Eligibility Criteria
Inclusion
- Type 2 Diabetes
- Stable insulin regimen of at least 2 injections per day
Exclusion
- Any smoking within the last 6 months. Smoking is not permitted at any time during this study.
- Subjects on insulin pump during 2 months prior to screening.
- Subjects with poorly-controlled asthma, clinically significant chronic obstructive pulmonary disease, or other significant respiratory disease.
Key Trial Info
Start Date :
September 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2000
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00424411
Start Date
September 1 1999
End Date
December 1 2000
Last Update
February 13 2007
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Burlingame, California, United States
2
Pfizer Investigational Site
Irvine, California, United States
3
Pfizer Investigational Site
Los Angeles, California, United States
4
Pfizer Investigational Site
Newport Beach, California, United States